Evidence map›Paper›PMID 35796948›Full record

ArticleApplied biochemistry and biotechnology2022

Isolation of Potential Compound from the Leaves of Elytraria acaulis and Evaluating Its Therapeutic Properties Using In Vitro Studies Against Ovarian Cancer.

P Priya, M Anbarasu, V S Christina, S Abdul Majeed, V Sivamurugan, R Lakshmi Sundaram

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

P PriyaPG & Research Department of Zoology, Pachaiyappa's College, Chennai, 600 030, Tamil Nadu, India. priyaponmudi79@gmail.com.ORCID http://orcid.org/0000-0002-2127-4233
M AnbarasuPG & Research Department of Chemistry, Pachaiyappa's College, Chennai, 600 030, Tamil Nadu, India.
V S ChristinaDepartment of Biotechnology, Faculty of Biomedical Sciences and Technology, SRI RAMACHANDRA Institute of Higher Education and Research (SRIHER), Deemed to Be University (DU), Chennai, 600 116, Tamil Nadu, India.
S Abdul MajeedPG and Research Department of Zoology, C. Abdul Hakeem College (Autonomous), Melvisharam, 632 509, Tamil Nadu, India.
V SivamuruganPG & Research Department of Chemistry, Pachaiyappa's College, Chennai, 600 030, Tamil Nadu, India. sivaatnus@gmail.com.
R Lakshmi SundaramCentral Research Facility (CRF), SRI RAMACHANDRA Institute of Higher Education and Research (SRIHER), Deemed to Be University (DU), Chennai, 600 116, Tamil Nadu, India.
Sri Ramachandra Institute of Higher Education and Research · INSathyabama Institute of Science and Technology · INTamil Nadu Dr. M.G.R. Medical University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was designed to isolate a potential compound from the extracts of Elytraria acaulis (E. acaulis) for ovarian cancer. n-Hexane, ethyl acetate, chloroform, acetone and methanol extract were taken using the Soxhlet method. Thin layer, column chromatography, NMR and MASS studies were done for the isolation and structural characterization of the compound. Finally, the novel compound (Z)-3-(2-methyl-3-oxoprop-1-en-1-yl) phenyl heptanoate was identified. MTT assay, cell morphology and cell cycle analysis were done to evaluate the anticancer property of the compound. In the MTT assay, the percentage of the cell viability treated with the isolated compound was decreased while increasing the concentration of the compound. Cancer cells treated with the isolated compound showed distinct morphological changes when compared to the control untreated cells. In the cell cycle analysis, the isolated compound induced a significant increase in the percentage of cells in G0/G1 phase and a decrease in the percentage of cells in the S phase and G2-M phase of the PA 1 cell lines. The cell cycle arrest induced by the isolated compound may account for its antiproliferative capacity. Hence, the novel compound isolated from E. acaulis can be a potent candidate in the designing of anticancer drugs.

Indexed as

ApoptosisOvarian NeoplasmsCell ProliferationCell SurvivalFemaleHumansPlant ExtractsPlant LeavesPlant ExtractsApoptosisCell cycleElytraria acaulisMTT assayNMROvarian cancer

Identifiers

PMID35796948
OpenAlexW4284700774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.